Skip to main content

Table 1 Incidence and duration of acute dermatolymphangioadenitis (ADLA) in filariasis-endemic areas.

From: Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature

Study

Annual incidence of ADLA in general population (per 1000)

Annual incidence of ADLA in 'patients' (per patient)

Mean duration of ADLA episode (days)

Study site

Notes

Bancroftian filariasis

Addiss 1999 [47]

--

2.1^

--

Haiti

 

Alexander 1999 [42]

31

--

16

Papua New Guinea

Only cases with fever and ADLA in lower limb

Babu 2005 [48]

85.0

1.6†

3.9

Orissa, India

 

Gasarasi 2000 [39]

33

--

8.6

Tanzania

 

Gyapong 1996 [40]

95.9

--

5.1

Ghana

 

Kanda 2004 [44]

--

1.5^

10.6

Haiti

 

Krishnamoorthy 1999 [45]

--

6.4‡

4.1

Tamil Nadu, India

 

Kron 2000 [52]

--

--

4.5

Philippines

 

Mathieu 2005 [49]

--

2.3^

7.3

Togo

 

McPherson 2006 [50]

--

1.6^

--

Guyana

 

Pani 1995 [21]

--

4.2^

4.1

Tamil Nadu, India

 

Ramaiah 1996 [41]

96.5

1.8†

3.6

Tamil Nadu, India

 

Sabesen 1992 [46]

49.8

6.0^

3.9

Tamil Nadu, India

 

Brugian filariasis

Pani 1989 [51]

--

4.9^

7.6^

4.9

5.8

Kerala, India

Stage 1 oedema

Stage 2 oedema

Rao 1982 [43]

371*

--

1.4

Kerala, India

Only cases with fever

Sabesen 1992 [46]

41.4

5.4

4.9

Kerala, India

 

Suma 2002 [32]

--

4.7^

--

Kerala, India

Restricted to patients with ≥ 2 ADLA episodes.

  1. ^Lymphoedema patients only
  2. ‡ Lymphoedema and hydrocele patients
  3. † Among persons with one or more ADLA episodes in 1-year observation period
  4. *Calculated from 7 month follow-up